|
Origin | Disease models | Biological function | Contributing factors | Artificial modification & loading methods | Articles |
|
Mouse bone marrow-derived MSCs (BM-MSCs) | Breast cancer | Suppress angiogenesis and tumor progression | miR-16 | / | Lee et al. [35] |
|
Human adult liver stem cells (HLSCs) | Hepatoma | Transfer genetic information that interferes with the deregulated survival and proliferation | miR451, miR223, miR31, and so on | / | Fonsato et al. [33] |
|
MSCs | Glioma | Reduce glioma xenograft growth in rat brain | miR-146b | Transfection and electroporation | Katakowski et al. [65] |
|
Mouse BM-MSCs | Pancreatic adenocarcinoma | Inhibit in vitro tumor growth | Paclitaxel | Incubation | Pascucci et al. [56] |
|
Human umbilical cord Wharton’s jelly mesenchymal stem cells (hWJMSCs) | Bladder tumor | Downregulated phosphorylation of Akt protein kinase and upregulated cleaved caspase 3 during the process of antiproliferation and proapoptosis | Akt and caspase 3 | / | Wu et al. [66] |
|
MSCs | Liver injury | Induces an anti-inflammatory effect | Cationized pullulan | Incubation | Tamura et al. [59] |
|
Mouse embryonic fibroblast (MEF) glioblastoma cells | / | Engineer exosomes containing Cre recombinase that have been used to identify functional delivery of exosomes across the blood-brain barrier to recipient neurons in the brain | Labeling of a target protein, Cre recombinase, with a WW tag | Transfection | Sterzenbach et al. [57] |
|
BM-MSCs | Colonic carcinoma gastric carcinoma | Promote VEGF and CXCR4 expression in tumor cells through ERK1/2 and p38 MAPK pathways | / | / | Zhu et al. [67] |
|
Mouse immature dendritic cells (imDCs) | Breast cancer | Target tumor therapy | Doxorubicin | Electroporation transfection | Tian et al. [50] |
|
Human umbilical cord-derived MSCs (hucMSCs) | Acute myocardial infarction | Accelerate endothelium cell proliferation, migration, and vessel formation | Platelet-derived growth factor D (PDGF-D) | Transfection | Ma et al. [55] |
|
BM-MSCs | Status epilepticus (SE) | Minimize the adverse effects of SE in the hippocampus and prevent SE-induced cognitive and memory impairments | / | / | Long et al. [68] |
|
BM-MSCs | Ameliorate inflammation-inducedpreterm brain injury | Ameliorate inflammation-induced neuronal cellular degeneration, reduce microgliosis, and prevent reactive astrogliosis | / | / | Drommelschmidt et al. [69] |
|
hucMSCs | PBMCs | Immunosuppressive function | / | / | Monguio-Tortajada et al. [70] |
|
Cardiomyocyte progenitor cell (CMPC) MSCs | Human microvascular endothelial cells (HMECs) and human umbilical vein endothelial cells (HUVECs) | Proangiogenic effects | Extracellular matrix metalloproteinase inducer (EMMPRIN) | / | Vrijsen et al. [29] |
|
MSCs | Breast cancer | Deliver antagomiRs to chemosensitize the BCCs and to prevent dormancy | Anti-miR-222/-223 | Transfection | Bliss et al. [71] |
|
BM-MSCs | PBMCs | Incorporated by monocytes, lowering the effect on lymphocyte populations | / | / | Di Trapani et al. [37] |
|
BM-MSCs | Hepatocellular carcinoma, ovarian cancer, Kaposi’s sarcoma | Induce in vitro cell cycle arrest and apoptosis or necrosis of different tumor cell lines and in vivo inhibit growth of established tumors | / | / | Bruno et al. [72] |
|
BM-MSCs | Breast cancer | Induce dormant phenotypes through the suppression of a target gene, MARCKS, which encodes a protein that promotes cell cycling and motility | miR-23b | / | Ono et al. [34] |
|
hucMSCs | Hepatitis C virus (HCV) | Suppress HCV RNA replication | let-7f, miR-145, miR-199a, and miR-221 | / | Qian et al. [36] |
|
BM-MSCs | Osteosarcoma | Suppress the migration of the 143B osteosarcoma cell line | miR-143 | Transfection | Shimbo et al. [54] |
|